A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

Phase 2

Completed

• Conditions: Mycobacterium Avium-Intracellulare Infection; HIV Infections

• Registration Number: NCT00002170
• Lead Sponsor: Agouron Pharmaceuticals

Brief Summary

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.

Detailed Description

Not available

Study Timeline

• Status Verified: 1999-05
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (5)

Harbor UCLA Med Ctr; 🇺🇸 Torrance, California, United States

Boston VA Med Ctr / 151; 🇺🇸 Boston, Massachusetts, United States

Rush Presbyterian - Saint Luke's Med Ctr; 🇺🇸 Chicago, Illinois, United States

Univ of California / San Diego Treatment Ctr; 🇺🇸 San Diego, California, United States

Baylor Univ; 🇺🇸 Houston, Texas, United States